Status:

COMPLETED

Micropulse Transscleral Diode Laser Cyclophotocoagulation (MP-TSCPC) as a Treatment Modality for Glaucoma Patients

Lead Sponsor:

Benha University

Conditions:

Glaucoma

Eligibility:

All Genders

3-70 years

Phase:

NA

Brief Summary

The study objective was to evaluate the efficacy and safety of transscleral cyclophotocoagulation (TSCPC) using micropulse diode laser treatment in patients with various types of glaucoma.

Detailed Description

Evaluation of the efficacy and safety of a new form of transscleral cyclophotocoagulation (TSCPC) using micropulse diode laser treatment in patients with various types of glaucoma. In this study, 810 ...

Eligibility Criteria

Inclusion

  • Patients previously diagnosed with glaucoma if they had uncontrolled Intraocular pressure despite maximal tolerated medical therapy.
  • Patients who are unable to maintain compliance with the prescribed topical medications.
  • Patients who need filtering glaucoma surgery for controlling Intraocular pressure but are not generally fit for the surgery.
  • Patients who refused incisional procedures like subscleral trabeculectomy.

Exclusion

  • Patients who were unable to give informed consent.
  • Patients who had undergone previous conventional transscleral diode laser cyclophotocoagulation (TSCPC).
  • Patients with significant scleral thinning defined as thinning of more than one clock hour noticed on scleral transillumination.
  • Patients with ongoing ocular infection or inflammation.

Key Trial Info

Start Date :

January 1 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

July 1 2021

Estimated Enrollment :

40 Patients enrolled

Trial Details

Trial ID

NCT05299281

Start Date

January 1 2020

End Date

July 1 2021

Last Update

March 29 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Benha University

Banhā, Other, Egypt, 13511

Micropulse Transscleral Diode Laser Cyclophotocoagulation (MP-TSCPC) as a Treatment Modality for Glaucoma Patients | DecenTrialz